MeRInO研究:弥散加权MRI作为口咽鳞癌放疗疗效预测生物标志物的研究
MeRInO研究是一项前瞻性观察性影像学研究,纳入中高危局部晚期口咽鳞状细胞癌(OPSCC)接受根治性放疗或同步放化疗的患者,在治疗前及放疗第3周行弥散加权MRI(DW-MRI),测量预设靶病灶(原发灶及淋巴结)的表观扩散系数(ADC)并计算变化值,随访记录各靶病灶疾病状态,主要目标是确定从基线至放疗第3周ADC变化的阈值,以识别治疗中的无应答亚组。
要点
- 中高危OPSCC根治性放化疗后仍有相当比例局部复发,需治疗中预测疗效的生物标志物。
- MeRInO研究在治疗前和放疗第3周行DW-MRI,测量原发灶和淋巴结ADC变化。
- 主要目标是确定预测无应答的ADC变化阈值,以支持个体化自适应治疗。
核心结论
- MeRInO研究旨在OPSCC中建立预测局部失败的ADC阈值,为使用DW-MRI改善头颈鳞癌治疗比提供关键步骤。
研究设计与样本
- MeRInO研究为前瞻性观察性影像学研究,纳入中高危局部晚期OPSCC接受根治性放疗或同步放化疗的患者。
- 患者在治疗前(MRI_1)和放疗第3周(MRI_2)行弥散加权MRI,对预设靶病灶(原发灶和淋巴结)测量ADC并计算变化。
- 随访记录各靶病灶的疾病状态。
主要发现
- 原文指出,迄今研究已发现治疗前与治疗中DW-MRI对比可能预测治疗反应。
- 原文指出,既往研究纳入所有亚部位和生物学亚型,需在特定头颈亚部位及相似生物学行为亚型中更稳健地建立阈值。
关键数值与推荐
- 主要目标为确定从基线至放疗第3周ADC变化的阈值,以识别治疗中的无应答亚组。
- ADC测量在每次扫描时对预先指定的靶病灶(原发灶和淋巴结)进行,并计算ADC变化。
临床怎么用
- 对中高危OPSCC根治性放化疗患者,可在治疗前和放疗第3周行DW-MRI测量原发灶及淋巴结ADC变化。
- ADC变化阈值一旦建立,可能用于治疗中识别无应答者并支持个体化自适应治疗策略。
局限性
- 原文指出,DW-MRI作为头颈鳞癌放疗中的预测生物标志物仍处于起步阶段。
- 原文指出,既往研究纳入所有亚部位和生物学亚型,可能影响阈值建立的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND BACKGROUND: A significant proportion of patients with intermediate and high risk squamous cell cancer of the oropharynx (OPSCC) continue to relapse locally despite radical chemoradiotherapy (CRT). The toxicity of the current combination of intensified dose per fraction radiotherapy and platinum based chemotherapy limits further uniform intensification. If a predictive biomarker for outcomes from CRT can be identified during treatment then individualised and adaptive treatment strategies may be employed. METHODS/DESIGN: The MeRInO study is a prospective observational imaging study of patients with intermediate and high risk, locally advanced OPSCC receiving radical RT or concurrent CRT Patients undergo diffusion weighted MRI prior to treatment (MRI_1) and during the third week of RT (MRI_2). Apparent diffusion coefficient (ADC) measurements will be made on each scan for previously specified target lesions (primary and lymph nodes) and change in ADC calculated. Patients will be followed up and disease status for each target lesion noted. The primary aim of the MeRInO study is to determine the threshold change in ADC from baseline to week 3 of RT that may identify the sub-group of non-responders during treatment. DISCUSSION: The use of DW-MRI as a predictive biomarker during RT for SCC H&N is in its infancy but studies to date have found that response to treatment may indeed be predicted by comparison of DW-MRI carried out before and during treatment. However, previous studies have included all sub-sites and biological sub-types. Establishing ADC thresholds that predict for local failure is an essential step towards using DW-MRI to improve the therapeutic ratio in treating SCC H&N. This would be done most robustly in a specific H&N sub-site and in sub-types with similar biological behaviour. The MeRInO study will help establish these thresholds in OPSCC.
引用
- Paterson C, Allwood-Spiers S, McCrea I, et al. Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clin Transl Radiat Oncol. 2017. PMID: 29657994. doi:10.1016/j.ctro.2016.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。